Health-related quality of life among persons with initial mild, moderate, and severe or critical COVID-19 at 1 and 12 months after infection: a prospective cohort study

Anouk Verveen1,2, Elke Wynberg3,4,5†, Hugo D. G. van Willigen4,5,6†, Udi Davidovich3,7, Anja Lok2,8,9, Eric P. Moll van Charante2,10,11, Menno D. de Jong5,6, Godelieve de Bree4,5, Maria Prins3,4,5, Hans Knoop1,2, Pythia T. Nieuwkerk1,2,5* and the RECoVERED Study Group

Abstract

Background: Currently, there is limited evidence about the long-term impact on physical, social and emotional functioning, i.e. health-related quality of life (HRQL) after mild or moderate COVID-19 not requiring hospitalization. We compared HRQL among persons with initial mild, moderate or severe/critical COVID-19 at 1 and 12 months following illness onset with Dutch population norms and investigated the impact of restrictive public health control measures on HRQL.

Methods: RECoVERED, a prospective cohort study in Amsterdam, the Netherlands, enrolled adult participants after confirmed SARS-CoV-2 diagnosis. HRQL was assessed with the Medical Outcomes Study Short Form 36-item health survey (SF-36). SF-36 scores were converted to standard scores based on an age- and sex-matched representative reference sample of the Dutch population. Differences in HRQL over time were compared among persons with initial mild, moderate or severe/critical COVID-19 using mixed linear models adjusted for potential confounders.

Results: By December 2021, 349 persons were enrolled of whom 269 completed at least one SF-36 form (77%). One month after illness onset, HRQL was significantly below population norms on all SF-36 domains except general health and bodily pain among persons with mild COVID-19. After 12 months, persons with mild COVID-19 had HRQL within population norms, whereas persons with moderate or severe/critical COVID-19 had HRQL below population norms on more than half of the SF-36 domains. Dutch-origin participants had significantly better HRQL than participants with a migration background. Participants with three or more COVID-19 high-risk comorbidities had worse HRQL than part participants with fewer comorbidities. Participants who completed the SF-36 when restrictive public health control measures applied reported less limitations in social and physical functioning and less impaired mental health than participants who completed the SF-36 when no restrictive measures applied.

†Elke Wynberg and Hugo D. G. van Willigen contributed equally to this work.

*Correspondence: pt.nieuwkerk@amsterdamumc.nl

1 Department of Medical Psychology (J3-2019-1), Amsterdam UMC location
AMC University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
With the COVID-19 pandemic having been ongoing for more than 2 years, increasing attention is being paid to the long-term impacts on physical, social and emotional functioning, i.e. the health-related quality of life (HRQL), following SARS-CoV-2 infection. Although many COVID-19 patients return to their pre-COVID-19 state of health after the acute phase of infection [1], appreciable numbers of persons report ongoing post-infection sequelae [2].

Previous studies have shown significantly impaired HRQL within the first months after illness onset [3–6]. To date, only a few studies have investigated the long-term HRQL of COVID-19 patients with follow-up periods of 12 months or beyond, showing mixed results with some studies reporting that patients still have impaired HRQL after 1 year [7–10], and others reporting most patients to have good physical and functional recovery [1, 11]. As these studies were almost exclusively conducted among previously hospitalized patients, an important gap in our knowledge remains since the majority of SARS-CoV-2 infections are asymptomatic or mildly symptomatic not requiring hospitalization, and it is well established that long-term post-infection sequelae is not restricted to individuals who initially had severe or critical COVID-19 requiring hospitalization [12].

Restrictive public health control measures to curb the spread of SARS-CoV-2 may also have a negative impact on the HRQL of COVID-19 patients. For example, being required to stay in isolation whilst recovering from COVID-19 can be socially isolating and impact mental health [13], and may continue to have a negative impact after recovery. In addition, general public health measures beyond the isolation period, such as national restrictions on social contacts, travel, work and leisure, may also negatively impact HRQL, irrespective of previous SARS-CoV-2 infection. The objectives of the present study are to compare HRQL among persons with initial mild, moderate or severe/critical COVID-19 at 1 and 12 months following illness onset using Dutch age- and sex-matched population HRQL norms, to investigate sociodemographic and clinical factors associated with impaired HRQL, and to investigate the impact of restrictive public health control measures on HRQL.

Methods
Study design and participants
The RECoVERED study is a cohort of individuals with laboratory-confirmed SARS-CoV-2 infection in the municipal region of Amsterdam, the Netherlands. Enrolment began on 11 May 2020 [14]. Non-hospitalized participants were identified from notification data at the Public Health Service of Amsterdam and enrolled within 7 days of diagnosis. Prospectively enrolled hospitalized participants were identified from admissions to the COVID-19 wards of the Amsterdam University Medical Centers (AUMC). Up to 30 June 2020, a number of hospitalized patients were included retrospectively within 3 months following SARS-CoV-2 infection. Eligibility criteria included laboratory confirmation of SARS-CoV-2 infection by reverse transcriptase polymerase chain reaction (RT-PCR), age 16–85 years, residing in the Amsterdam region, and adequate understanding of Dutch or English. Excluded were nursing home residents and individuals with mental disorders likely to interfere with adherence to study procedures. For the present analyses, we included all participants with at least 1 month of follow-up and at least one completed HRQL questionnaire on 1 December 2021.

Study procedures
Study visits at enrolment (D0) and day 7 (D7) of follow-up took place at the participant’s home or on the hospital ward whilst subsequent visits took place at one of two study sites. Past medical history and sociodemographic data were collected during the first month of follow-up by participant interview and/or medical records. Physical measurements (heart rate, respiratory rate [RR], oxygen saturation [SpO₂]), were measured at D0 and D7, or retrieved from hospital records for retrospectively enrolled participants.

Definitions
Illness onset was defined as the first day on which COVID-19 symptoms were experienced for symptomatic
patients or date of COVID-19 diagnosis for asymptomatic patients.

Clinical severity groups were defined based on WHO COVID-19 severity criteria 16: mild disease as having a RR <20/min and SpO2>94% on room air at both D0 and D7; moderate disease as having a RR 20–30/min and/or SpO2 90–94% or receiving oxygen therapy at D0 or D7; severe disease as having a RR>30/min and/or SpO2<90% or receiving oxygen therapy at D0 or D7; critical disease as ICU admission due to COVID-19 at any point.

High-risk comorbidities were those identified by the WHO as being associated with severe COVID-19 [15] and include the following: cardiovascular disease (including hypertension), diabetes mellitus, chronic pulmonary disease (excluding asthma), cancer, immunosuppression (excluding HIV, including previous organ transplantation), previous psychiatric illness, renal disease, liver disease and dementia. BMI was coded in kg/m² as <25, underweight or normal weight; 25–30, overweight; or >30, obese. Migration background was categorized as Dutch and non-Dutch origin based on the country of birth of the participant and their parents [16, 17]. Participants of non-Dutch background were further classified as originating from a OECD high-income (HIC) or low-/middle-income country (LMIC) [18]. Highest educational level was categorized as low/medium (none, primary/secondary school; vocational training) or high (university-level).

Measurement of HRQL

At months 1 and 12 of follow-up, participants completed the Medical Outcomes Study Short Form 36-item health survey (SF-36) [19]. The SF-36 comprises 36 items that address the following 8 dimensions reflecting the respondent’s HRQL: ability to perform usual and vigorous activities (physical functioning), ability to participate in social and occupational activities (social functioning, physical role functioning, and emotional role functioning), mood (mental health dimension), amount of energy and pain (vitality/fatigue and pain dimensions) and perceived current health (general health perceptions). Each dimension is scored from 0 to 100, with higher scores indicating better HRQL.

Restrictive public health measures

We defined the progression of restrictive measures that was applied in the Netherlands between 10 June 2020, when the first HRQL questionnaire was to be completed, and 1 December 2021, i.e. the date of closure of our database for the present analysis, based on time periods during which specific public health measures were implemented. We distinguished the following restrictive measures: evening curfew (23 January 2021 to 28 April 2021) and closure of bars, cafes and restaurants (14 October 2020 to 5 June 2021), primary schools, including daycare (14 December 2020 to 8 February 2021), secondary and vocational education (14 December 2020 to 1 March 2021), higher education (16 December to 25 April 2021), non-essential shops (15 December 2020 to 28 April 2021), entertainment venues (4 November 2020 to 18 May 2021) and gyms/sport centres (15 December 2020 to 18 May 2021) [20]. Due to the overlap in restrictive measures, we divided them in two groups based on time period and scope. We combined closure of bars, cafes, restaurants, entertainment venues and gym/sport centres and further refer to them as restrictions in leisure activities. We combined closure of educational institutions, non-essential shops and evening curfew and further refer to them as restrictions in non-leisure activities.

Statistical analysis

Characteristics of participants at enrolment were compared between clinical severity groups, using chi-squared tests or analysis of variance, where appropriate.

Participants’ SF-36 scores were compared with published age- and sex-matched Dutch reference adult population norms [21]. The 8 dimensions of the SF-36 scores were converted to standard scores on the basis of the scores of an age- and sex-matched representative reference sample of the adult Dutch population. Standard scores were calculated by dividing the difference between the participants’ SF-36 score and the mean score of the matched reference population by the standard deviations (SDs) of the reference population, as described previously [22]. A standard score thus indicates how many SDs the observed SF-36 score falls below or above the score of the reference population. Consequently, scores of the reference population are set at 0. Because it is similar to the effect size calculation, a mean standard score of 0.20 is considered to indicate a small deviation from the reference population [22], and mean standard scores of 0.50 and 0.80 are considered to indicate moderate and large deviations from the reference population, respectively [23].

We compared HRQL among persons with initially mild, moderate or severe/critical COVID-19 at 1 and 12 months following illness onset and sociodemographic and clinical factors at illness onset up to 1 month associated with more impaired HRQL using mixed linear models. Standard scores relative to the Dutch population for the eight SF-36 dimensions were the dependent variables. COVID-19 severity group and time since illness onset (month 1, month 12) were included as fixed effects. Correlation between repeated measurements within participants was taken into account by including a random intercept. Mixed linear models are maximum likelihood
estimation-based techniques which can handle the presence of missing data and still provide valid results without the need for imputation of data under the missing at random assumption.

We considered the following characteristics for inclusion as fixed covariates: BMI category (normal weight, overweight, obese), number of COVID-19 high-risk comorbidities (<3, ≥3), migration background (Dutch-origin, originating from a HIC, originating from a LMIC), highest completed educational level (low/medium, high). We initially looked at the impact on HRQL of having 0, 1, 2 or ≥ 3 comorbidities. If there was a significant impact of number of comorbidities on HRQL, the difference was between the group of participants with ≥ 3 comorbidities versus those with <3 comorbidities. We therefore decided to proceed using the variable with only 2 categories, i.e. <3 and ≥3. We generated a multivariate model for each of the SF-36 dimensions using a backwards selection approach until all sociodemographic and baseline clinical characteristics in the final model had p-values <0.05. COVID-19 severity group and time since illness onset were kept in all models irrespective of statistical significance. If SF36-36 dimensions were significantly associated with the number of comorbidities in the multivariate model, we subsequently entered the specific comorbidities in the model, after removing the variable number of comorbidities, and investigated how much of the variance in the particular SF-36 dimension was explained by each comorbidity.

For the COVID-19 severity groups at month 1 and month 12, we checked whether the 95% confidence intervals of the estimated mean standard scores of the eight SF-36 dimensions excluded the value zero, which would indicate that HRQL is significantly different from the age- and sex-matched population norms.

We verified if at least one of the restrictions in leisure activities applied (yes/no) and/or at least one of the restrictions in non-leisure activities applied (yes/no) on the date that a participant completed the SF-36. The restrictive measures were added to the final multivariate mixed linear model for each of the eight SF-36 dimensions as a time-dependent covariate to examine impact on HRQL.

As we had a priori determined that the variables initial COVID-19 severity and time (month 1, month 12) should be kept in all models irrespective of statistical significance, another 6 variables were investigated as potential determinants, of which 3 variables had 3 categories, so that a total of 11 parameters had to be estimated. Consequently, we would need to include at least 220 participants per predictor variable for a continuous outcome measure. Statistical analysis was conducted using SPSS version 28 (IBM Corp, Armonk, NY). Two-sided p-values <0.05 were considered to indicate statistical significance.

**Results**

By 1 December 2021, a total of 269 (77%) out of 349 participants enrolled in the cohort had completed at least one HRQL questionnaire. A total of 111 participants completed a questionnaire at both month 1 and month 12, 101 only at month 1 and 57 only at month 12. Of note, not all participants had reached the month 12 time point at closure of the database for the present analyses. Characteristics at enrolment are shown in Table 1. Participants who did not complete questionnaires more often originated from a LMIC, had a lower educational level, more often had severe/critical COVID-19 and had more often been hospitalized (See Additional file 1: Table S1).

**Impact on HRQL of initial COVID-19 severity**

Table 2 shows the impact on HRQL of initial COVID-19 severity, time since illness onset and sociodemographic and clinical characteristics according to the final multivariate mixed linear models adjusted for confounders. All final models included clinical severity and time since illness onset, as predetermined, and migration background. The model for physical functioning and general health additionally included the number of comorbidities (Table 2). On 7 out of 8 SF-36 dimensions, participants with mild COVID-19 had significantly better HRQL than participants with moderate or severe/critical COVID-19, whereas there was no statistically significant difference in HRQL between participants with moderate and severe/critical COVID-19. The exception was the mental health dimension where participants with mild COVID-19 had significantly better mental health than participants with moderate COVID-19, but there were no significant differences between participants with mild or moderate versus severe/critical COVID-19. HRQL was significantly better at month 12 compared with month 1 on seven out of eight SF-36 dimensions. On the general health perceptions dimension, month 1 scores were not significantly different from month 12 scores.

Dutch-origin participants had significantly better HRQL than participants with a migration background from either HIC or LMIC countries on the dimensions physical, social and role physical functioning, bodily pain and vitality. Dutch-origin participants and participants from LMIC had significantly better HRQL than participants from HIC on the dimensions general health, role emotional and mental health.

Participants with three or more COVID-19 high-risk comorbidities had significantly worse HRQL on the dimensions physical functioning and general health than
participants with less than three COVID-19 high-risk comorbidities. We subsequently looked at the impact of specific comorbidities. Immunosuppression explained the largest percentage of variance in physical function, i.e. 4.6% followed by previous psychiatric illness, i.e. 1.9%. Previous psychiatric illness explained the largest percentage of variance in general health, i.e. 3.6%, followed by immunosuppression, i.e. 3.3% and by the category “other” (renal disease, liver disease and dementia), i.e. 2.9%. Remaining comorbidities explained less than 1% of variance and are therefore considered of negligible influence.

HRQL compared with age- and gender-matched populations norms
One month after illness onset, participants had HRQL scores below population norms on seven out of eight SF-36 dimensions (Fig. 1 A–G). These HRQL scores were derived from the final multivariate mixed linear models adjusted for confounders. Deviations from the

| Table 1 | Sociodemographic, clinical (baseline and COVID-19-related) characteristics of RECoVERED study participants |
|-----------------|---------------------------------|-----------------|-----------------|-----------------|-----------------|
|                | Mild N=82                        | Moderate N=122  | Severe/critical N=65 | P-value         |
| Sex            |                                 |                 |                  |                 |
| Male           | 38 (46%)                        | 67 (55%)        | 40 (62%)         | 0.18            |
| Female         | 44 (54%)                        | 55 (45%)        | 25 (38%)         |                 |
| Age (years), mean (SD) | 43 (17)                  | 48 (15)         | 57 (12)          | <0.001          |
| BMI category   |                                 |                 |                  | <0.001          |
| Normal weight  | 48 (59%)                        | 51 (42%)        | 14 (22%)         |                 |
| Overweight     | 21 (26%)                        | 42 (34%)        | 29 (47%)         |                 |
| Obese          | 12 (15%)                        | 29 (24%)        | 16 (31%)         |                 |
| Migration background |                                 |                 |                  | <0.001          |
| Dutch origin   | 61 (75%)                        | 73 (61%)        | 35 (55%)         |                 |
| OECD high income | 11 (14%)                  | 20 (17%)        | 4 (6%)           |                 |
| OECD low/middle income | 9 (11%)               | 27 (22%)        | 35 (39%)         |                 |
| Highest level of education |                                 |                 |                  | <0.001          |
| None, primary, secondary or vocational training | 14 (17%)    | 51 (42%)        | 35 (55%)         |                 |
| University education | 67 (83%)              | 70 (58%)        | 29 (45%)         |                 |
| Number of COVID-19 high-risk comorbidities |                                  |                 |                  | 0.032           |
| <3             | 80 (98%)                        | 113 (93%)       | 56 (86%)         |                 |
| 3 or more      | 2 (2%)                         | 9 (7%)          | 9 (14%)          |                 |
| COVID-19 high-risk comorbidities |                                 |                 |                  |                 |
| Cardiovascular | 11 (13.4%)                      | 31 (25.4%)      | 30 (46.9%)       | 0.001           |
| Diabetes mellitus | 3 (3.7%)                     | 10 (8.2%)       | 15 (23.4%)       | 0.001           |
| Chronic respiratory disease | 1 (1.2%)                 | 8 (6.6%)        | 10 (15.6%)       | 0.003           |
| Cancer         | 5 (6.1%)                        | 7 (5.7%)        | 4 (6.3%)         | 0.99            |
| Immunodeficiency | 0                             | 3 (2.5%)        | 2 (3.1%)         | 0.31            |
| Previous psychiatric illness | 5 (6.1%)               | 7 (5.7%)        | 3 (4.7%)         | 0.93            |
| Other*         | 11 (13.6%)                      | 33 (27.3%)      | 16 (25.0%)       | 0.064           |
| Hospital admission | 3 (4%)                        | 53 (43%)        | 61 (94%)         | <0.001          |
| ICU admission  | 0                              | 0               | 32 (49%)         | <0.001          |

Continuous variables presented as mean (standard deviation) and compared using analysis of variance; categorical and binary variables presented as n(%) and compared using the Pearson χ² test (or Fisher exact test if n<5)

Clinical severity groups defined as mild as having a RR<20/min and SpO₂ on room air >94% at both days 0 and 7; moderate disease as having a RR 20–30/min, SpO₂ 90–94% and/or receiving oxygen therapy at day 0 or 7; severe disease as having a RR>30/min or SpO₂ < 90% at day 0 or 7; critical disease as requiring ICU admission

COVID-related comorbidities are based on WHO Clinical Management Guidelines and include: cardiovascular disease (including hypertension), chronic pulmonary disease (excluding asthma), renal disease, liver disease, cancer, immunosuppression (excluding HIV, including previous organ transplantation), previous psychiatric illness and dementia

BMI body mass index, OECD Organisation for Economic Co-operation and Development, HIC high-income country, LMIC low- or middle-income country, ICU intensive care unit

* Other includes renal disease, liver disease and dementia
Table 2 Impact on HRQL of initial COVID-19 severity, time since enrolment and sociodemographic- and baseline clinical characteristics

| Parameter                          | Reference = mild | Reference = month 1 | Reference = Dutch-origin | Reference = <3 comorbidities |
|------------------------------------|------------------|---------------------|--------------------------|-----------------------------|
|                                    | Moderate         | Severe/critical     | Month 12                 | Low/middle-income country   | High-income country         | ≥ 3 comorbidities            |
| Physical functioning               | −0.47 (−0.77 to −0.17) * | −0.65 (−1.04 to −0.27) * | 0.87 (0.61 to 1.14) * | −0.50 (−0.90 to −0.11) * | −0.85 (−1.17 to −0.52) * | −0.54 (−1.06 to −0.03) * |
|                                    | p < 0.001        | p < 0.001           | p < 0.001                | p = 0.013                   | p < 0.001                  | p = 0.003                   |
| Role physical                      | −0.38 (−0.64 to −0.13) * | −0.52 (−0.84 to −0.10) * | 1.24 (1.01 to 1.46) * | −0.28 (−0.56 to −0.0010) * | −0.44 (−0.77 to −0.62) * | Not in model                |
|                                    | p = 0.003        | p = 0.002           | p < 0.001                | p = 0.046                   | p = 0.011                  | Not in model                |
| Bodily pain                        | −0.48 (−0.73 to −0.23) * | −0.71 (−1.03 to −0.39) * | 0.64 (0.42 to 0.87) * | −0.42 (−0.69 to −0.15) * | −0.71 (−1.04 to −0.37) * | Not in model                |
|                                    | p < 0.001        | p < 0.001           | p < 0.001                | p = 0.003                   | p < 0.001                  | Not in model                |
| Vitality                           | −0.58 (−0.83 to −0.32) * | −0.69 (−1.02 to −0.36) * | 0.91 (0.69 to 1.14) * | −0.31 (−0.59 to −0.03) * | −0.93 (−1.27 to −0.60) * | Not in model                |
|                                    | p = 0.001        | p < 0.001           | p < 0.001                | p = 0.030                   | p < 0.001                  | Not in model                |
| Social functioning                 | −0.49 (−0.82 to −0.16) * | −0.53 (−1.38 to −0.27) * | 1.13 (0.90 to 1.36) * | −0.44 (−0.72 to −0.15) * | −1.03 (−1.38 to −0.68) * | Not in model                |
|                                    | p = 0.004        | p < 0.001           | p < 0.001                | p = 0.003                   | p < 0.001                  | Not in model                |
| Mental health                      | −0.30 (−0.53 to −0.07) * | −0.15 (−0.45 to 0.14) | 0.36 (0.15 to 0.56) * | −0.18 (−0.43 to 0.07) | −1.09 (−1.40 to −0.79) * | Not in model                |
|                                    | p = 0.01         | p = 0.311           | p < 0.001                | p = 0.161                   | p < 0.001                  | Not in model                |
| Role emotional                     | −0.34 (−0.60 to −0.08) * | −0.43 (−0.76 to −0.10) * | 0.53 (0.30 to 0.76) * | −0.96 (−1.31 to −0.62) * | −0.24 (−0.53 to 0.05) | Not in model                |
|                                    | p = 0.012        | p = 0.012           | p < 0.001                | p < 0.001                   | p = 0.101                  | Not in model                |
| General health                     | −0.53 (−0.77 to −0.28) * | −0.55 (−0.87 to −0.23) * | 0.11 (−0.12 to 0.33) | −0.10 (−0.37 to 0.17) | −0.50 (−0.82 to −0.17) * | −0.46 (−0.89 to −0.02) * |
|                                    | p < 0.001        | p < 0.001           | p = 0.355                | p = 0.457                   | p = 0.003                  | p = 0.042                   |

Parameter estimates are regression coefficients from mixed linear models adjusted for confounders. All models include a random intercept. CI denotes confidence interval. Parameter estimates can be interpreted as effect sizes (Cohen’s d) with values of 0.2, 0.5 and 0.8 indicating small, medium and large effects respectively.

*p < 0.05
Fig. 1 HRQL compared with general population norms. Participants with initial mild COVID-19 are shown in green, initial moderate COVID-19 in blue and initial severe/critical COVID-19 in red. Solid line at zero indicates no difference compared with general population. Values are estimate marginal means with 95% confidence intervals from mixed linear models adjusted for confounders.
population norms were highest for social functioning (−1.68, indicating a large effect, for participants with moderate COVID-19) and lowest for bodily pain (−0.20, indicating a small effect, for patients with mild COVID-19). On the general health dimension, participants with mild COVID-19 scored within population norms, whereas participants with moderate or severe/critical COVID-19 had scored below population norms.

After 12 months, HRQL was within population norms on the dimensions bodily pain and role physical in all clinical severity groups. On the dimensions physical functioning, social functioning, vitality, role emotional and general health, participants with initial mild COVID-19 had HRQL within population norms, whereas participants with initial moderate or severe/critical COVID-19 still had HRQL below population norms. On the mental health dimension, only participants with initial moderate COVID-19 had HRQL below population norms. The absolute and unadjusted differences to the population norms are shown in Fig. 2.

**Impact of restrictive public health measures on HRQL**

Participants who completed a HRQL questionnaire when restrictions in leisure activities applied reported less impairments in mental health than participants who completed a HRQL questionnaire when no restrictions in leisure activities applied ((mean (se): −0.15 (0.08) versus −0.38 (1.0), p=0.039). Participants who completed a HRQL questionnaire when restrictions in non-leisure activities applied reported less limitations in social functioning (mean (se): −0.67 (0.11) versus −0.96 (0.09), p=0.042) and in physical functioning (mean (se): −0.68 (0.17) versus −0.99 (0.15), p=0.039) than participants who completed a HRQL questionnaire when no restrictions in these activities applied.

**Discussion**

In this prospective cohort among participants with mild, moderate and severe/critical initial COVID-19 severity, HRQL was substantially impaired 1 month after illness onset. Twelve months after illness onset, participants with initial mild COVID-19 had HRQL comparable with population norms, whereas participants with initial moderate or severe/critical COVID-19 still had impaired HRQL on five out of eight HRQL dimensions. Interestingly, HRQL was less impaired during periods when restrictive public health control measures applied than in periods when no restrictive measures applied.

To the best of our knowledge, only four previous studies investigating HRQL about 1 year after SARS-CoV-2 infection included non-hospitalized participants. Steinbeis et al. found that HRQL improved over time among patients with higher disease severity, whereas it remained constant among patients in the lower severity categories [24]. Seeßle et al. did not report about HRQL in relation to COVID-19 severity or time since illness onset [10]. Han et al. found that patients with mild COVID-19 not requiring hospitalization who were experiencing persistent symptoms 1 year after COVID-19 had poorer HRQL than patients without persistent symptoms [25]. O’Kelly et al. found that non-hospitalized patients had better mental HRQL and tended to have better physical HRQL than hospitalized patients 1 year after COVID-19 [26].

Our finding that participants with initial mild COVID-19 had HRQL that was, on average, comparable with population norms after 12 months is reassuring, as long-term post-infection sequelae can also occur after mild disease [14]. Participants with initial moderate or severe/critical COVID-19 still had impaired HRQL on more than half of the HRQL dimensions compared with population norms after 12 months. Because there was no assessment of participants’ pre-COVID-19 HRQL, we cannot draw definite conclusions about whether participants had returned to their pre-COVID-19 level of HRQL or if their level of HRQL was still impaired.

At month 12, participants with initial moderate or severe COVID-12 still had impaired HRQL on the dimensions physical, social and role emotional functioning, vitality and general health with moderate to large deviations from general population norms. A previous study comparing these HRQL domains between individuals with and without chronic conditions (arthritis, chronic lung disease, congestive heart failure, diabetes and ischemic heart disease) found decrements of a small to moderate magnitude on these HRQL domains among those with chronic health conditions (26). The time since onset of these chronic conditions was not specified so that participants may have already adapted to living with these chronic conditions. Nevertheless, this implies that the impact of COVID-19 on HRQL after 12 months may still be substantial even if the effect of comorbidity on HRQL is taken into account.

In general, HRQL was less impaired during periods when restrictive public health control measures applied than during periods without restrictive measures. We had expected the opposite as in general populations worldwide, decreases in subjective well-being have been reported as a consequence of restrictive measures [27]. Our result are consistent with social comparison theory according to which it would be expected that participants feel less impaired if other people are also restricted in what they can do. Conversely, if others are no longer restricted in their activities, participants may experience more limitations [28].

Being a migrant from either a LMIC or HIC was associated with having worse HRQL, but this association was
Fig. 2  Mean unadjusted HRQL scores compared with mean general population scores. General population is shown in black, participants with initial mild COVID-19 are shown in green, initial moderate COVID-19 in blue and initial severe/critical COVID-19 in red. Dotted line indicates the general population mean. Values are unadjusted mean scores with 95% confidence intervals.
more pronounced for HIC. Residing in a foreign country during a global pandemic with an unfamiliar health system when becoming ill can be expected to be particularly challenging. Being more isolated from traditional support networks such as friends and families may also have led to feelings of loneliness and contributed to a negative impact on HRQL. Possibly, the negative impact of COVID-19 on HRQL was less pronounced for participants from LIC because they are more accustomed to cope with adverse circumstances. Another explanation might be that HIC persons could be more accustomed to high quality of care and have higher expectations for such care. It could be that Dutch health care systems potentially fair less well than HIC persons would expect based on their experience back home. This might not be the case for LIC where expectations from the health services are low in comparison to the Netherlands. Clearly, our finding of a more severe impact on HRQL among migrants from HIC compared with LIC needs to be corroborated in other studies.

A point of caution: we compared HRQL with Dutch general population norms in the absence of an uninfected (SARS-CoV-2 negative) control group. These norms were collected before the COVID-19 pandemic. If the COVID-19 pandemic would have a negative impact on the general population’s HRQL, this would render comparing pandemic outcomes with pre-pandemic norms inappropriate. However, the negative impacts of the pandemic on the well-being of general populations worldwide have been reported to be mild and transient [29, 30].

A limitation of this study is that the Dutch population norms were not stratified according to the presence of comorbidities. Of the persons included in the Dutch population norms, 48% had no chronic health condition, 29% had one condition and 23% had more than one condition, but HRQL normative data are not available separately for these groups. Participants with initial moderate or severe/critical COVID-19 more often had medical comorbidities, possibly relating to lower pre-COVID-19 HRQL. Nevertheless, only two of the HRQL domains were affected by the number of comorbidities, i.e. physical functioning and general health perceptions, but these were among the domains that remained below populations norms at month 12.

Participants with initial severe/critical COVID-19, previously hospitalized, a lower educational level and migrants from LMIC were less likely to complete HRQL questionnaires and to be included in the present HRQL study. Given that these factors were also associated with impaired HRQL, this may have resulted in an underestimation of the impact of COVID-19 on HRQL. Another limitation is that persons with mental disorders likely to interfere with adherence to study procedures were not eligible to participate. About 5% of the hospitalized persons were excluded for this reason, and for non-hospitalized persons, this was not registered. Exclusions concerned persons with acute severe mental illness such as delirium and persons with Alzheimer’s disease or intellectual disabilities. Therefore, our results cannot be generalized to persons with delirium, Alzheimer’s disease or intellectual disabilities.

This study also has several strengths. The vast majority of our participants had initial mild or moderate COVID-19 not requiring hospitalization. Currently, this is an understudied group with respect to long-term impacts on HRQL after COVID-19. Our prospective cohort study also follows participants from illness onset, thereby minimizing selection bias resulting from individuals self-referring due to poor HRQL. Another strength is our long follow-up period, allowing us to study truly long-term HRQL impacts of COVID-19.

Conclusions

Twelve months after illness onset, participants with initial mild COVID-19 had, on average, HRQL comparable with population norms, whereas participants with initial moderate or severe/critical COVID-19 still had impaired HRQL on more than half of the HRQL dimensions. Being a migrant from a HIC was associated with more impaired HRQL. HRQL was less impaired during periods when restrictive public health measures applied than in periods when no restrictions applied.

Abbreviations

AUMC: Amsterdam University Medical Centres; BMI: Body mass index; COVID-19: Coronavirus disease 2019; D0: Day 0 (baseline); D7: Day 7; HIC: High-income country; HRQL: Health-related quality of life; ICU: Intensive care unit; LMIC: Low-/middle-income country; OECD: Organisation for Economic Co-operation and Development; RR: Respiratory rate; RT-PCR: Reverse transcriptase polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; SD: Standard deviation; SF-36: Medical Outcomes Study Short Form 36-item health survey; SpO2: Saturation of peripheral oxygen; WHO: World Health Organization.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12916-022-02615-7.

Additional File 1: Table S1. Comparison of demographic and clinical characteristics of RECoVERED study participants who did and did not complete at least 1 HRQL questionnaire.

Acknowledgements

The authors wish to thank all RECoVERED study participants. In addition, we wish to thank all members of the RECoVERED Study Group, listed below. RECoVERED Study Group.

Public Health Service of Amsterdam: Ivette Agard, Jane Ayal, Floor Cavdar, Marianne Craanen; Annemarieke Deuring, Annelies van Dijk, Ertan Ersan, Laura del Grande, Joost Hartman, Nelleke Koedoot, Tjalling Leenstra, Romy Lebbink,
the Netherlands. Department of Medical Microbiology & Infection Prevention, Center for Urban Mental Health, University of Amsterdam, Amsterdam, the Netherlands. Department of Infectious Diseases, Amsterdam Public Health, Amsterdam, The Netherlands. Department of Psychiatry, Amsterdam University Medical Centres: Joost van den Aardweg, Joyce van Assem, Marjine van Beek, Thrya Blankert, Maartje Dijkstra, Oriane Figaroa, Leah Frenkel, Marit van Gils, Jelle van Haga, Xiaoquan (Alvin) Han, Agnes Harskamp-Helwerda, Mette Hazenberg, Soemeja Hidad, Nina de Jong, Neeltje Kootstra, Lara Kuijt, Colin Russell, Karlijn van der Straten, Annelou van der Veen, Bas Verkaik, Gerben-Rienk Visser.

Authors’ contributions
Conceptualization: AV, EW, HW, UD, AL, EMC, MJ, GB, MP, HK, PN. Data curation: AV, EW, HW. Formal analysis: AV, PN. Funding acquisition: MJ, GB, MP, HK, PN. Methodology: AV, EW, UD, AL, EMC, MP, HK, PN. All authors read and approved the final manuscript.

Funding
This publication is part of the project “Long-term mental health trajectories in recovered COVID-19 patients: exploring the interplay of psychosocial and biological factors affecting health-related quality of life” with project number 1043003201001002 of the research programme COVID-19, financed by the Netherlands Organisation for Health Research and Development (ZonMw). It was embedded in the project RECoVERED with project number 1010062010002 of the research programme Infectieziektenbestrijding 3 2019-2023, also financed by ZonMw. This work was additionally supported by the Public Health Service of Amsterdam [Research & Development grant number 21-14]. H.K. received additional funding from “ReCoVer: A Randomised Controlled Trial testing the efficacy of Cognitive Behavioural Therapy for preventing chronic post-infectious fatigue among patients diagnosed with COVID-19” with project number 10430012010025 of the research programme COVID-19, financed by ZonMw.

Availability of data and materials
Taking legal restrictions into account, the data collected for this study are available on request via the corresponding author up to 15 years after the end of the study.

Declarations
Ethics approval and consent to participate
This study was approved by the medical ethical review board of the AUMC Ethics approval and consent to participate. Taking legal restrictions into account, the data collected for this study are available on request via the corresponding author up to 15 years after the end of the study. Consent for publication All authors have given their consent for publication. Competing interests The authors declare that they have no competing interests.

Author details
1 Department of Medical Psychology (J3-2019-1), Amsterdam UMC location AMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. 2 Amsterdam Public Health, Amsterdam, The Netherlands. 3 Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, the Netherlands. 4 Department of Infectious Diseases, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands. 5 Amsterdam Institute for Infection and Immunity, Infectious Diseases, Amsterdam, the Netherlands. 6 Department of Medical Microbiology & Infection Prevention, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands. 7 Department of Social Psychology, University of Amsterdam, Amsterdam, the Netherlands. 8 Department of Psychiatry, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands. 9 Center for Urban Mental Health, University of Amsterdam, Amsterdam, the Netherlands. 10 Department of Public & Occupational Health, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands. 11 Department of General Practice, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.

Received: 9 June 2022 Accepted: 18 October 2022

Published online: 02 November 2022

References
1. Huang LX, Yao Q, Gu XY, Wang QY, Ren LL, Wang YM, et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747–58.
2. Whitaker M, Elliott J, Chadeau-Hyam M, Riley S, Darzi A, Cooke G, et al. Persistent symptoms following SARS-CoV-2 infection in a random community sample of 508,707 people. Nat Commun. 2022;13:1957.
3. Chen KY, Li T, Gong FH, Zhang JS, Li XK. Predictors of health-related quality of life and influencing factors for COVID-19 patients, a follow-up at one month. Front Psychiatry. 2020;11. https://doi.org/10.3389/fpsyt.2020.010668.
4. der Sar-van V, der Bruggen S, Talman S, Boonman-de Winter L, de Mol M, Hoefman E, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. Respir Med. 2021;176. https://doi.org/10.1016/j.rmed.2020.106272.
5. van den Borst B, Peters JB, Brink M, Schoon Y, Bleeker-Rovers CP, Schers H, et al. Comprehensive health assessment 3 months after recovery from acute coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73:e1089–e98. https://doi.org/10.1093/cid/ciaa1750.
6. Jacobs LG, Paleoudis EG, Lesky-Diri Bari D, Nyrenda T, Friedman T, Gupta A, et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One. 2020;15(12). https://doi.org/10.1371/journal.pone.0248882.
7. Betschart M, Rezek S, Unger I, Ott N, Beyer S, Roni A, et al. One year follow-up of physical performance and quality of life in patients surviving COVID-19: a prospective cohort study. Swiss Med Wkly. 2021;151:w30072. https://doi.org/10.4414/smw.2021.w30072.
8. Erber J, Wiessner JR, Zimmermann GS, Barthel P, Burian E, Lohofer F, et al. Longitudinal assessment of health and quality of life of COVID-19 patients requiring intensive care—an observational study. J Clin Med. 2021;10. https://doi.org/10.3390/jcm10235469.
9. Gambarini L, Mazzoli CA, Prediletto I, Sintonen H, Scaramuzzo G, Allegri D, et al. Health-related quality of life profiles, trajectories, persistent symptoms and pulmonary function one year after ICU discharge in invasively ventilated COVID-19 patients, a prospective follow-up study. Respir Med. 2021;189:106665.
10. Seelig J, Wartenboer T, Hippchen T, Simon J, Kirchner M, Lim A, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. Clin Infect Dis. 2022;74:1191–8.
11. Tesserore E, Handgraaf S, Poncet A, Achard M, Hofer S, Carballo S, et al. Symptoms and quality of life at 1-year follow-up of patients discharged after an acute COVID-19 episode. Swiss Med Wkly. 2021;151:w30093.
12. Castanères D, Kohn L, Davurin M, Detollenaere J, Maertens de Noordhout C, Jongh P-D, et al. Long COVID: pathophysiology–epidemiology and patient needs. Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Center (KCE). 2021. KCE Reports 344. D/2021/10.273/31. Available from: https://www.kce.fgov.be/sites/default/files/2021-11/KCE_344C_Long_Covid.Short_report.pdf. Accessed 15 Aug 2022.
13. Fancourt D, Steptoe A, Bu FF. Trajectories of anxiety and depressive symptoms during enforced isolation due to COVID-19 in a longitudinal observational study. Lancet Psychiatry. 2021;8:141–9.
14. Wynberg E, van Willigen HDG, Dijkstra M, Boyd A, Kootstra NA, van den Aardweg JG, et al. Evolution of COVID-19 symptoms during the first 12 months after illness onset. Clin Infect Dis. 2022;75:e482–90.
15. World Health Organization. COVID-19 Clinical management: living guidance. 2021. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2. Accessed 15 Aug 2022.
16. Strons K, Kulu-Glasgow I, Ayegamie C. The utility of ‘country of birth’ for the classification of ethnic groups in health research: the Dutch experience. Ethnic Health. 2009;14:255–69. https://doi.org/10.1080/13557860802509206.
17. Centraal Bureau voor de Statistiek. Migratieachtergrond. Available from: https://www.cbs.nl/nl-nl/onzediensten/methoden/begrippen/migraatieachtergrond. Accessed 15 Aug 2022.
18. OECD. DAC List of ODA Recipients. 2021. Available from: https://www.oecd.org/dac/financing-sustainable-development/development-finan-ce-standards/daclist.htm. Accessed 15 Aug 2022.
19. Ware JE. Scoring the SF-36. SF-36 Health Survey: Manual and Interpretation Guide, 1993.
20. Tijdlijn van coronamaatregelen. Rijksinstituut voor Volksgezondheid en Milieu; 2022. Updated 22-03-22. Available from: https://www.rivm.nl/gedragsonderzoek/tijdlijn-maatregelen-covid. Accessed 15 Aug 2022.

21. Aaronson NK, Muller M, Cohen PDA, Essink-Bot ML, Feikkes M, Sanderman R, et al. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol. 1998;51:1055–68.

22. Lettinga KD, Verbon A, Nieuwkerk PT, Jonkers RE, Gersons BPR, Prins JM, et al. Health-related quality of life and posttraumatic stress disorder among survivors of an outbreak of legionnaires disease. Clin Infect Dis. 2002;35:11–7.

23. Cohen J. Statistical power analysis for the behavioral sciences: Academic press; 2013.

24. Steinbeis F, Thibeault C, Doellinger F, Ring RM, Mittermaier M, Ruuwé-Glosenkamp C, et al. Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: an observational longitudinal study over 12 months. Respir Med. 2022;191. https://doi.org/10.1016/j.rmed.2021.106709.

25. Han JH, Womack KN, Tenforde MW, Files DC, Gibbs KW, Shapiro NI, et al. Associations between persistent symptoms after mild COVID-19 and long-term health status, quality of life, and psychological distress. Influenza Other Respir Viruses. 2022. https://doi.org/10.1111/irv.12980.

26. Alonso J, Ferrer M, Gandek B, Ware JE Jr, Aaronson NK, Mosconi P, et al. IQOLA Project Group. Health-related quality of life associated with chronic conditions in eight countries: results from the International Quality of Life Assessment (IQOLA) Project. Qual Life Res. 2004;13:283–98.

27. O’Kelly B, Vidal L, Avramovic G, Broughan J, Connolly SP, Cotter AG, et al. Assessing the impact of COVID-19 at 1-year using the SF-12 questionnaire data from the anticipate longitudinal cohort study. Int J Infect Dis. 2022;118:236–43. https://doi.org/10.1016/j.ijid.2022.03.013.

28. Festinger L. A theory of social comparison processes. Hum Relat. 1954;7:117–40.

29. Manchia M, Gathier AW, Yapici-Eser H, Schmidt MV, de Quervain D, van Ameloot T, et al. The impact of the prolonged COVID-19 pandemic on stress resilience and mental health: a critical review across waves. Eur Neuropsychopharmacol. 2022;55:22–83.

30. Gijzen M, Shields-Zeeman L, Kleinjan M, Kroon H, van der Roest H, Boiler L, et al. The Bittersweet Effects of COVID-19 on Mental Health: results of an online survey among a sample of the Dutch population five weeks after relaxation of lockdown restrictions. Int J Environ Res Public Health. 2020;17(7):233. https://doi.org/10.3390/ijerph1707233.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.